Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

(2019) Michelle L. O'Donoghue et al.   CIRCULATION

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

(2018) Michel R. Langlois et al.   CLINICAL CHEMISTRY

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

(2018) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comparison of Low-density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation

(2018) Seth S. Martin et al.   JAMA Cardiology

High lipoprotein(a) and high risk of mortality

(2018) Anne Langsted et al.   EUROPEAN HEART JOURNAL

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials

(2018) Peter Willeit et al.   LANCET

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack

(2017) Young Sup Byun et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

(2017) Robert P Giugliano et al.   LANCET

Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United StatesHighlights

(2016) Steve Varvel et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Structure, function, and genetics of lipoprotein (a)

(2016) Konrad Schmidt et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

(2016) Børge G. Nordestgaard et al.   JOURNAL OF LIPID RESEARCH

Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels

(2016) Connor A. Emdin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

‘LDL-C’ = LDL-C + Lp(a)-C

(2015) Calvin Yeang et al.   CURRENT OPINION IN LIPIDOLOGY

Mendelian randomization studies

(2015) Brian A. Ference   CURRENT OPINION IN LIPIDOLOGY

Lipoprotein(a) Levels in Familial Hypercholesterolemia

(2014) Rodrigo Alonso et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein(a)-cholesterol: A significant component of serum cholesterol

(2011) Kiyoko Kinpara et al.   CLINICA CHIMICA ACTA

Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study

(2011) Stefania Lamon-Fava et al.   JOURNAL OF LIPID RESEARCH

Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement Procedures

(2010) W. G. Miller et al.   CLINICAL CHEMISTRY

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies

(2010) Simon Thompson et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Assessing the Performance of Prediction Models

(2009) Ewout W. Steyerberg et al.   EPIDEMIOLOGY